Celcuity (Celcuity) EBIT per Share : $-2.58 (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Celcuity EBIT per Share?

Celcuity's EBIT per Share for the three months ended in Mar. 2024 was $-0.60. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.58.

During the past 3 years, the average EBIT per Share Growth Rate was -44.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was -36.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Celcuity's EBIT per Share or its related term are showing as below:

CELC' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -49.6 Med: -34.6 Max: -5.3
Current: -44.3

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Celcuity was -5.30% per year. The lowest was -49.60% per year. And the median was -34.60% per year.

CELC's 3-Year EBIT Growth Rate is ranked worse than
88.12% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs CELC: -44.30

Celcuity's EBIT for the three months ended in Mar. 2024 was $-20.21 Mil.

Celcuity EBIT per Share Historical Data

The historical data trend for Celcuity's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celcuity EBIT per Share Chart

Celcuity Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.72

-0.92

-2.12

-2.48

-2.47

Celcuity Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.49	-0.60	-0.77	-0.60	-0.60

Celcuity EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Celcuity's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-58.453	/	23.679
=	-2.47

Celcuity's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.212	/	33.612
=	-0.60

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.58

Celcuity (NAS:CELC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Celcuity EBIT per Share Related Terms

Thank you for viewing the detailed overview of Celcuity's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Celcuity (Celcuity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446

Website

https://www.celcuity.com

Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).

Executives

Richard E Buller	director	C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
David Dalvey	director	C/O BLUE ROCK ADVISORS, INC., 80 SOUTH EIGHTH STREET SUITE 3915, MINNEAPOLIS MN 55402
Leo Furcht	director	C/O CELCUITY, 16305 36TH AVENUE N., #100, MINNEAPOLIS MN 55445
Brian F Sullivan	director, 10 percent owner, officer: Chief Executive Officer	16305 36TH AVENUE N, MINNEAPOLIS MN 55446
Polly A. Murphy	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Richard Nigon	director	CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Lance G. Laing	director, 10 percent owner, officer: Chief Science Officer, VP	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Vicky Hahne	officer: Chief Financial Officer	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Maureen Therese Cronin	director	C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446